Table 5 Results of scintigraphic parameters in patients who had bile duct complications
Case and immunosuppression | Case 1 CSA | Case 2 TAC | Case 3 CSA to TAC | Case 4 CSA |
|---|---|---|---|---|
Complications, time of the onset of treatment after LTx | Bile duct stricture, 4 months | Bile duct stricture, 1.5 months | Bile duct stricture, 5 months | Bile leakage after the removal of T-tube, 1 month |
Treatment | Dilatation and bile duct stent placement by ERCP, PTCD | Dilatation and bile duct stent placement by ERCP, PTCD | Dilatation and bile duct stent placement by ERCP | Bile duct stent placement by ERCP, PTCD |
3-month HEF (%) | 46 | 14 | 13 | 29 |
Bilirubin, 3-month follow-up (μmol/l) | 38 | 59 | 41 | 16 |
1-year HEF (%) | 37 | 17 | 26 | 41 |
Bilirubin, 1-year follow-up (μmol/l) | 8 | 146 | 142 | 18 |